Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

Originally posted here:
Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Scroll to Top